Advances in Drug Treatments on Immunomodulatory and Neuroprotective Targets in Multiple Sclerosis

Guest Editors:

Dr. Daniel Ortuño-Sahagún
Instituto de Investigación en Ciencias Biomédicas (IICB), Centro Universitario de Ciencias de las Salud (CUCS), Universidad de Guadalajara, Guadalajara, Mexico

Dr. Lenin Pavon
Laboratorio de Psicoinmunología, Dirección de Investigaciones en Neurociencias Instituto Nacional de Psiquiatria Ramón de la Fuente Muñiz, Ciudad de México 14370, Mexico

Deadline for manuscript submissions:
closed (15 February 2023)

Message from the Guest Editors

Multiple Sclerosis (MS) is an immune-mediated demyelinating disease mainly affecting the Central Nervous System. Advances in comprehending this pathology involve understanding the complex interactions between the different systems, not only nervous and immune (IS) but also the endocrine and metabolic, also with the various tissues and organs involved, as well as considering their response to treatments. There is currently no cure for MS, and treatment is mainly based on Disease-Modifying Therapies that act on the IS to decrease the relapse rate and the progression of brain lesions, thus limiting neurological deterioration. Identifying subgroups of patients with MS is crucial to understanding the disease's evolution and the response to treatment since subgroups of patients share some characteristics that define variations in the drug effect, diversity of molecular targets, and differences in response to treatment. For these reasons, it is essential to understand the molecular processes further causing MS heterogeneity and varying therapeutic responses, concentrating on immunomodulatory and neuroprotective targets, to advance clinical treatments and better understand the illness.

mdpi.com/si/134392

Special Issue

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us